“… A 2018 internal presentation the company labeled “privileged and confidential” acknowledges that observational studies show a
“somewhat consistent” association between prenatal exposure to Tylenol and neurodevelopmental disorders. Another presentation slide acknowledges that larger meta-analyses — reviews summarizing multiple scientific studies — found an association, but notes weaknesses of these studies like confounding variables and subjectivity in measuring autistic traits.
“Johnson & Johnson divested its consumer health business years ago, and all rights and liabilities associated with the sale of its over-the-counter products, including Tylenol (acetaminophen), are owned by
Kenvue,” a Johnson & Johnson spokesman said in a statement.
… Hearings before the Court of Appeals for the Second Circuit in the class action suit against Kenvue will begin Oct. 9. Judge Denise Cote granted summary judgement for Kenvue in September 2023, after
tossing the scientific testimony from experts for Keller Postman, citing the “great public health implications” of pregnant women not having the drug.…”